Literature DB >> 23329253

History of methicillin-resistant Staphylococcus aureus (MRSA) surgical site infection may not be a contraindication to ventral hernia repair with synthetic mesh: a preliminary report.

C W Hicks1, J A Blatnik, D M Krpata, Y W Novitsky, M J Rosen.   

Abstract

PURPOSE: A history of methicillin-resistant Staphylococcus aureus (MRSA) surgical site infection presents a significant surgical dilemma as to the risk of subsequent mesh infection, even if no active infection is present. We investigated the outcomes of ventral hernia repair with synthetic mesh in patients with prior MRSA surgical site infections (SSIs).
METHODS: All patients with a clean wound but prior MRSA SSI undergoing open ventral hernia repair with mesh by a single surgeon over a 3-year period were reviewed for the development of any major (need for readmission, operative debridement, or mesh removal) or minor SSI. All patients received peri-operative intravenous vancomycin and prolonged suppressive oral trimethoprim/sulfamethoxazole or doxycycline.
RESULTS: Ten patients (male = 7, female = 3) with clean wounds and a history of MRSA SSI underwent open ventral hernia repair with retrorectus synthetic mesh placement. Mean follow-up was 13.5 ± 3.3 months. Overall, two patients (20 %) developed SSIs (minor = 2, major = 0). Both SSIs were successfully managed with therapeutic oral antibiotics and local wound care without need for surgical debridement or mesh removal. There have been no hernia recurrences in any of the patients.
CONCLUSIONS: Preliminary results suggest that history of MRSA infection may not be a contraindication to the use of synthetic mesh for ventral hernia repair. Macroporous lightweight meshes, combined with use of prolonged suppressive antibiotics and sublay retromuscular mesh placement that provides complete tissue coverage, should be further investigated as an acceptable prosthetic choice when planning a complex ventral hernia repair in the setting of prior MRSA SSI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23329253     DOI: 10.1007/s10029-012-1035-x

Source DB:  PubMed          Journal:  Hernia        ISSN: 1248-9204            Impact factor:   4.739


  43 in total

1.  Does a history of wound infection predict postoperative surgical site infection after ventral hernia repair?

Authors:  Jeffrey A Blatnik; David M Krpata; Yuri W Novitsky; Michael J Rosen
Journal:  Am J Surg       Date:  2012-03       Impact factor: 2.565

2.  Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention.

Authors:  C M Brandt; W W Sistrunk; M C Duffy; A D Hanssen; J M Steckelberg; D M Ilstrup; D R Osmon
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

Review 3.  Biomaterials for abdominal wall hernia surgery and principles of their applications.

Authors:  P K Amid; A G Shulman; I L Lichtenstein; M Hakakha
Journal:  Langenbecks Arch Chir       Date:  1994

4.  Affinity of Staphylococcus epidermidis to various prosthetic graft materials.

Authors:  S Demirer; I E Geçim; K Aydinuraz; H Ataoğlu; M A Yerdel; E Kuterdem
Journal:  J Surg Res       Date:  2001-07       Impact factor: 2.192

5.  Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection.

Authors:  John J Engemann; Yehuda Carmeli; Sara E Cosgrove; Vance G Fowler; Melissa Z Bronstein; Sharon L Trivette; Jane P Briggs; Daniel J Sexton; Keith S Kaye
Journal:  Clin Infect Dis       Date:  2003-02-07       Impact factor: 9.079

6.  Evaluation of new prosthetic meshes for ventral hernia repair.

Authors:  J W A Burger; J A Halm; A R Wijsmuller; S ten Raa; J Jeekel
Journal:  Surg Endosc       Date:  2006-07-24       Impact factor: 4.584

7.  Factors affecting wound complications in repair of ventral hernias.

Authors:  T J White; M C Santos; J S Thompson
Journal:  Am Surg       Date:  1998-03       Impact factor: 0.688

8.  More than 150 consecutive open umbilical hernia repairs in a major Veterans Administration Medical Center.

Authors:  Buckminster Farrow; Samir Awad; David H Berger; Daniel Albo; Liz Lee; Anu Subramanian; Charles F Bellows
Journal:  Am J Surg       Date:  2008-11       Impact factor: 2.565

9.  A novel approach for salvaging infected prosthetic mesh after ventral hernia repair.

Authors:  J A Trunzo; J L Ponsky; J Jin; C P Williams; M J Rosen
Journal:  Hernia       Date:  2009-02-12       Impact factor: 4.739

10.  Antimicrobial-impregnated surgical incise drapes in the prevention of mesh infection after ventral hernia repair.

Authors:  Brian R Swenson; Theresa R Camp; Daniel P Mulloy; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2008-02       Impact factor: 2.150

View more
  5 in total

1.  A retrospective review and observations over a 16-year clinical experience on the surgical treatment of chronic mesh infection. What about replacing a synthetic mesh on the infected surgical field?

Authors:  C Birolini; J S de Miranda; E M Utiyama; S Rasslan
Journal:  Hernia       Date:  2014-02-09       Impact factor: 4.739

Review 2.  Methicillin-resistant Staphylococcus aureus (MRSA): antibiotic-resistance and the biofilm phenotype.

Authors:  Kelly M Craft; Johny M Nguyen; Lawrence J Berg; Steven D Townsend
Journal:  Medchemcomm       Date:  2019-03-14       Impact factor: 3.597

Review 3.  Surgical site infection: the "Achilles Heel" of all types of abdominal wall hernia reconstruction.

Authors:  D J Tubre; A D Schroeder; J Estes; J Eisenga; R J Fitzgibbons
Journal:  Hernia       Date:  2018-10-01       Impact factor: 4.739

4.  Infection prevention using affinity polymer-coated, synthetic meshes in a pig hernia model.

Authors:  Jeffrey A Blatnik; Thimma R Thatiparti; David M Krpata; Sean T Zuckerman; Michael J Rosen; Horst A von Recum
Journal:  J Surg Res       Date:  2017-05-08       Impact factor: 2.192

Review 5.  Risks and Prevention of Surgical Site Infection After Hernia Mesh Repair and the Predictive Utility of ACS-NSQIP.

Authors:  Robert Beaumont Wilson; Yasser Farooque
Journal:  J Gastrointest Surg       Date:  2022-01-21       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.